1000 resultados para E-Serial Licenses Update
Resumo:
The Fiscal Division newsletter, published weekly during session and periodically during the interim.
Resumo:
The Fiscal Division newsletter, published weekly during session and periodically during the interim.
Resumo:
The Fiscal Division newsletter, published weekly during session and periodically during the interim.
Resumo:
The Fiscal Division newsletter, published weekly during session and periodically during the interim.
Resumo:
Systemic fungal infections remain a significant cause of mortality in neutropenic and immunocompromised patients, despite advances in their diagnosis and treatment. The incidence of such infections is rising due to the use of intensive chemotherapy regimens in patients with solid tumours or haematological cancers, the increasing numbers of allogeneic haematopoietic stem cell and solid organ transplants, and the use of potent immunosuppressive therapy in patients with autoimmune disorders. In addition, the epidemiology of systemic fungal infections is changing, with atypical species such as Aspergillus terreus and zygomycetes becoming more common. Treatment has traditionally focused on empirical therapy, but targeted pre-emptive therapy in high-risk patients and prophylactic antifungal treatment are increasingly being adopted. New treatments, including lipid formulations of amphotericin B, second-generation broad-spectrum azoles, and echinocandins, offer effective antifungal activity with improved tolerability compared with older agents; the potential impact of these treatments is reflected in their inclusion in current treatment and prophylaxis guidelines. New treatment strategies, such as aerosolized lipid formulations of amphotericin B, may also reduce the burden of mortality associated with systemic fungal infections. The challenge is to identify ways of coupling potentially effective treatments with early and reliable identification of patients at highest risk of infection.
Resumo:
The Fiscal Division newsletter, published weekly during session and periodically during the interim.
Resumo:
The Fiscal Division newsletter, published weekly during session and periodically during the interim.
Resumo:
ABSTRACT: Conventional mechanical ventilators rely on pneumatic pressure and flow sensors and controllers to detect breaths. New modes of mechanical ventilation have been developed to better match the assistance delivered by the ventilator to the patient's needs. Among these modes, neurally adjusted ventilatory assist (NAVA) delivers a pressure that is directly proportional to the integral of the electrical activity of the diaphragm recorded continuously through an esophageal probe. In clinical settings, NAVA has been chiefly compared with pressure-support ventilation, one of the most popular modes used during the weaning phase, which delivers a constant pressure from breath to breath. Comparisons with proportional-assist ventilation, which has numerous similarities, are lacking. Because of the constant level of assistance, pressure-support ventilation reduces the natural variability of the breathing pattern and can be associated with asynchrony and/or overinflation. The ability of NAVA to circumvent these limitations has been addressed in clinical studies and is discussed in this report. Although the underlying concept is fascinating, several important questions regarding the clinical applications of NAVA remain unanswered. Among these questions, determining the optimal NAVA settings according to the patient's ventilatory needs and/or acceptable level of work of breathing is a key issue. In this report, based on an investigator-initiated round table, we review the most recent literature on this topic and discuss the theoretical advantages and disadvantages of NAVA compared with other modes, as well as the risks and limitations of NAVA.
Resumo:
The Fiscal Division newsletter, published weekly during session and periodically during the interim.
Resumo:
The Fiscal Division newsletter, published weekly during session and periodically during the interim.
Resumo:
The Fiscal Division newsletter, published weekly during session and periodically during the interim.
Resumo:
The Fiscal Division newsletter, published weekly during session and periodically during the interim.
Resumo:
The Fiscal Division newsletter, published weekly during session and periodically during the interim.
Resumo:
The Fiscal Division newsletter, published weekly during session and periodically during the interim.
Resumo:
The Fiscal Division newsletter, published weekly during session and periodically during the interim.
